Publikationen, an denen er mitarbeitet M. Díez Campelo (24)

2019

  1. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy

    Blood

2015

  1. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study

    Haematologica, Vol. 100, Núm. 10, pp. 1294-1300

2014

  1. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations

    Leukemia

2013

  1. Uptake and delivery of antigens by mesenchymal stromal cells

    Cytotherapy, Vol. 15, Núm. 6, pp. 673-678

2012

  1. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation

    Transfusion, Vol. 52, Núm. 5, pp. 1086-1091

  2. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: Are they present at diagnosis or are they induced by lenalidomide?

    Haematologica, Vol. 97, Núm. 10, pp. 1608-1611

  3. Optimisation of mesenchymal stromal cells karyotyping analysis: Implications for clinical use

    Transfusion Medicine, Vol. 22, Núm. 2, pp. 122-127

  4. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

    Annals of Hematology, Vol. 91, Núm. 12, pp. 1887-1895

2010

  1. Liver function tests and absolute lymphocyte count at day +100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant

    American Journal of Hematology, Vol. 85, Núm. 4, pp. 290-293

  2. The role of immature platelet fraction in acute coronary syndrome

    Thrombosis and Haemostasis

2009

  1. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome

    Leukemia, Vol. 23, Núm. 4, pp. 664-672

  2. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population

    Haematologica, Vol. 94, Núm. 7, pp. 975-983

2008

  1. Clinical and prognostic value of discrepancies in microsatellite dna regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting

    Transplantation, Vol. 86, Núm. 7, pp. 983-990

  2. Optimization of mesenchymal stem cell expansion procedures by cell separation and culture conditions modification

    Experimental Hematology, Vol. 36, Núm. 8, pp. 1014-1021

  3. Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health Scale Plus the Type of Onset Can Predict Survival Rates and the Duration of Immunosuppressive Therapy

    Biology of Blood and Marrow Transplantation, Vol. 14, Núm. 10, pp. 1163-1171

  4. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes

    Haematologica, Vol. 93, Núm. 9, pp. 1301-1309

2006

  1. Chronic graft-versus-host disease: Pathogenesis and clinical management

    Drugs, Vol. 66, Núm. 8, pp. 1041-1057

  2. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD)

    Biology of Blood and Marrow Transplantation, Vol. 12, Núm. 9, pp. 936-941

2005

  1. CD34+ cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation

    Leukemia and Lymphoma, Vol. 46, Núm. 2, pp. 177-183

  2. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena

    American Journal of Hematology, Vol. 78, Núm. 4, pp. 302-305